UK markets close in 4 hours 26 minutes

Oxford BioMedica plc (OXB.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
407.50-9.50 (-2.28%)
As of 11:27AM GMT. Market open.
Full screen
Previous close417.00
Open405.00
Bid405.50 x 0
Ask408.50 x 0
Day's range402.00 - 419.93
52-week range276.62 - 1,294.00
Volume16,601
Avg. volume156,212
Market cap392.273M
Beta (5Y monthly)1.04
PE ratio (TTM)20.37
EPS (TTM)0.20
Earnings date15 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1,065.00
  • Globe Newswire

    Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer

    The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer Oxford, UK – 22

  • Globe Newswire

    Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million

    Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces exchange of contracts for the sale of its Windrush Court facility (the "Property") to Kadans Science Partner (“Kadans”) for £60 million. Completion is due to occur on or around the 18th November 2022. The sale proceeds of £60 million exceed the target o

  • Globe Newswire

    Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree

    The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree Partia